We are leveraging our
knowledge of new autophagy
biology to create new therapeutics
Our Pipeline
Samsara is leveraging its knowledge of new autophagy biology to rapidly advance multiple drug candidates to the clinic – promising new therapies designed to treat serious rare genetic diseases and neurodegenerative disorders with a strong genetic component. These diseases all have limited or no known treatment options.
We focus on identifying novel targets and mechanisms which have a strong genetic linkage to dysfunctional autophagy, and pair this new biology with the appropriate genetically driven disease where autophagy plays a driving role, and where we have generated strong in-house evidence of disease modification.
The Lysoseeker™ Platform
A unique approach for discovering new autophagy therapeutics.
Neurodegeneration
What if we could tackle the cause of Alzheimer’s and Parkinson’s Disease?
Rare Monogenic Disease
What if we could offer real hope for serious rare genetic diseases?
Our Pipeline
Samsara is leveraging its knowledge of new autophagy biology.
Samsara Therapeutics Establishes Scientific Advisory Board
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics
More additions to the Samsara Therapeutics team
We’re pleased to report that we’ve further strengthened our team in Oxford.
Neurodegeneration, lysosomal dysfunction and autophagy
There is a desperate need for novel therapies that can prevent the progressive neurodegeneration in debilitating diseases of ageing, such as Alzheimer’s, Parkinson’s and Huntington’s Disease.
New home and strengthening our scientific team
It’s a busy time for Samsara Therapeutics as we move into our new purpose-built labs and offices in the Wood Centre for Innovation in Oxford.
© 2021 Samsara Therapeutics | Legal Information | Privacy
© 2021 Samsara Therapeutics
Legal Information | Privacy